Hair Loss Treatments Aren’t the Problem—Delivery Is

Androgenetic alopecia (AGA) or more commonly known as pattern hair loss, is the most prevalent cause of hair thinning in both men and women. In men, the first sign of AGA begins through the thinning of the temples, which gradually spreads to the hair line and crown, resulting in complete baldness. In females, AGA is characterized as thinning in the middle of the head down to the hairline and rarely ever progresses to complete baldness.  

As AGA is influenced by genetic and hormonal factors, there are a variety of treatment strategies that target the hormonal driver of follicular miniaturization as well as compounds that improve the overall wellbeing of the scalp to induce/prolong hair growth. Established medications such as minoxidil, finasteride, and dutasteride remain the most widely studied options, while bioactive peptides like GHK-Cu represent a newer category of adjunctive support 

Understanding how these treatments work, who they are best suited for, and how they differ in effectiveness and safety; is essential for developing rational, individualized treatment plans for both men and women experiencing hair loss. 

Understanding Androgenetic Alopecia 

A. Pathophysiology 

1. Minoxidil (Men & Women) 

Category: Follicular growth stimulant 

Minoxidil is considered the first-line therapy for both men and women with AGA. It does not alter hormones but instead works directly on the hair cycle. Unlike the other AGA treatments that will be discussed, minoxidil does not alter with DHT. Instead, it works directly on hair follicles to stimulate hair growth and prolong the active phase of the hair cycle. 

Mechanism: 

Minoxidil is a prodrug – it becomes active (minoxidil sulfate) when metabolized by sulfotransferase in the scalp. Minoxidil sulfate acts as a potassium channel opener, promoting vasodilation and enhancing dermal papilla activity, the structure responsible for hair cycle regulation. This prolongs the anagen (growth) and shortens the telogen (resting) phase, and increases overall hair shaft diameter. Under the prolonged and scheduled use of minoxidil, this can lead to thicker, longer-growing hairs and an improved density. Minoxidil is effective in the early to moderate stages of AGA.  

Clinical Role: 

Minoxidil is available in 2-5% topical and low-dose oral formulations, with the oral formulations as an alternative for those who cannot tolerate topical administration. Because minoxidil does not target hormones, minoxidil is the preferred first-line therapy in women, including those of reproductive age.  

Limitations: 

Treatment requires long-term adherence, discontinuation of minoxidil treatment often leads to the reversal of hair growth gained during the treatment. Furthermore, some patients experience an initial shedding phase as hair follicles transition into a synchronized growth cycle. Topical formulations containing alcohol or propylene glycol may also cause scalp irritation, dryness, or contact dermatitis, which can further affect patient compliance.     

However, tolerability and delivery remain key challenges with traditional formulations. This has led to the development of alternative delivery systems, such as NOVOLUX™ Hair, designed to improve scalp compatibility and patient adherence.

2. Finasteride (Primarily Men) 

Category: Hormonal suppression (5-alpha reductase inhibitor, Type II) 

An oral medication, finasteride targets the hormonal driver of male pattern hair loss by reducing DHT levels in susceptible scalp follicles.  

Mechanism: 

Finasteride works by selectively inhibiting 5-alpha reductase type II enzymes in the scalp; these enzymes are responsible for converting testosterone into DHT. DHT levels are reduced by approximately 60-70%, decreasing androgen signaling at the dermal papilla and slowing the hair thinning process and increasing hair count and thickness over time.  

Clinical Role: 

Clinical studies support finasteride as an efficacious treatment option in men with early to moderate AGA, especially in the vertex and mid-scalp. It does not typically restore a completely receded hairline but can slow the progression and improve overall hair density.  In women, finasteride is rarely prescribed in women with childbearing potential due to its hormonal interruption pathways, DHT is critical for male fetal development. However, finasteride is prescribed under specialist supervision in post-menopausal women.  

Limitations: 

Similarly to minoxidil, patient compliance is important for results. Discontinuation leads to a gradual return to baseline hair loss within several months. Potential side effects such as decreased libido, erectile dysfunction, and other sexual dysfunctions are seen in a minority of individuals.   

3. Dutasteride (Primarily Men, More Potent) 

Category: Hormonal suppression (5-alpha reductase inhibition, type I and II)  

Dutasteride is the more potent androgen inhibitor in comparison to finasteride, working very similarly by reducing DHT levels in the scalp.  

Mechanism: 

Dutasteride inhibits both type I and II enzymes of 5-alpha reductase enzymes, with type II being predominant in hair follicles and type I is also present in sebaceous glands and scalp tissue. By blocking both pathways, dutasteride reduces DHT levels by more than 90%, resulting in a stronger androgen suppression.  

Clinical Role: 

A stronger suppression of DHT often translates into greater increases in hair count and thickness compared to finasteride. Clinical studies have demonstrated superior efficacy in improving vertex and mid-scalp density. Because there is hormonal suppression, dutasteride is not commonly used in women of childbearing potential due to development abnormalities, it is only ever used in post-menopausal women and under specialist supervision. Dutasteride is used in patients with more advanced hair loss or who have stopped seeing results in finasteride therapy.  

Limitations: 

Because the suppression of DHT is stronger, there is an increased likelihood of hormonal side effects in susceptible individuals. Dutasteride requires continuous long-term use to maintain results. When discontinued, DHT level return to baseline and hair loss progression gradually resumes over time. 

4. GHK-Cu (Copper Peptide) 

Category: Regenerative and follicular microenvironment modulator 

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) directly induces follicles into a prolonged growth phase. It is naturally occurring in human plasma and tissues and it has been studied for its role in wound healing and tissue remodeling.  

Mechanism: 

GHK-Cu functions as a copper-binding signaling peptide that influences gene expression, it stimulates dermal papilla cell activity, increases collagen and extracellular matrix production, promotes angiogenesis, and modulates inflammatory cytokines. By improving the structural and vascular environment surrounding the follicle, it aims to create conditions that support sustained hair growth.  

Clinical Positioning: 

Currently, GHK-Cu has limited clinical evidence and is considered an adjunctive therapy, potentially complementing hormonal suppression (finasteride, dutasteride), or growth stimulation (minoxidil) strategies instead of acting as an independent hair treatment option. 

The Overlooked Variable: Formulation & Delivery 

No matter how pharmacologically effective a molecule can perform, if the delivery system is inadequate it simply won’t work. For AGA, clinical outcomes depend on how efficiently and consistently the active ingredients can reach the hair follicle and trigger the hair regrowth mechanisms. 

A. Common Vehicles 

Propylene glycol is frequently used as a penetration enhancer and solubilizing agent in topical formulations, and is commonly used in conventional minoxidil solutions. Propylene glycol improves drug diffusion across the stratum corneum. However, propylene glycol commonly causes contact dermatitis, pruritus, scaling, and irritation in scalp treatments. This plethora of adverse effects can reduce patient compliance which is pivotal in long-term use of these products to combat AGA.   

Ethanol (alcohol) is also a popular solvent used due to its ability or rapidly solubilize active ingredients and enhances skin permeation of the actives. Ethanol also disrupts the barrier of the stratum corneum which causes more drug to permeate as well as accelerating drying time. Repeat exposure of ethanol can compromise the barrier integrity of the scalp, increasing transepidermal water loss, and contributing to scalp dryness, irritation, and inflammation. These are all factors that accelerate hair shedding in individuals that have sensitive scalps.  

Hydroalcoholic mixtures combine ethanol and water (and often with PG) to balance drug solubility and penetration. These mixtures are very popular for topical AGA mixtures because they allow sufficient drug dissolution while maintaining relatively rapid evaporation. Due to the combination of irritant causing delivery vehicles, the both carry the associated adverse effects of propylene glycol and ethanol. 

In terms of drug stability and delivery, rapid alcohol evaporation can alter drug concentrations meant to be applied onto the scalp surface, leading to inconsistent concentrations that are absorbed. These systems are not engineered for follicular targeting, resulting in variable delivery to the dermal papilla which can lead to inconsistent results – another factor to take into consideration when it comes to patient compliance.  

Additionally, peptide-based molecules such as GHK-Cu have unique stability challenges. Peptides in general are susceptible to degradation, oxidation, or conformational instability depending on pH, solvent system, and exposure conditions. Suboptimal formulations can reduce the bioactivity of these peptides before follicular penetration occurs.  

These traditional vehicles are used to improve drug solubility and penetration, however they are not specifically optimizing follicular delivery or contribute to long-term scalp barrier health. These limitations highlight the importance of an advanced delivery system that improves therapeutic performance and tolerability in the AGA treatment space.  

This is where advanced delivery systems become critical. Newer formulations designed for targeted follicular delivery aim to improve consistency, reduce irritation, and enhance overall treatment outcomes. For example, NOVOLUX™ Hair is designed to optimize delivery of active ingredients while maintaining scalp barrier integrity, addressing many of the limitations seen in traditional alcohol- or solvent-based systems.

Effective AGA Treatment: It’s More Than Just the Drug

AGA is hormonally and genetically mediated condition that presents differently in men and women, requiring specific/individualized therapeutic strategies depending on age, gender, and severeness of AGA. Minoxidil is premier option for both sexes due to their direct stimulation of follicular activity without the hormonal interference of DHT. Finasteride and dutasteride serve as hormone suppressors of DHT, offering stronger hair regrowth and is much more commonly prescribed for men.  

Emerging options such as GHK-Ci aim to improve follicular microenvironment and support regenerative processes, though they currently lack the clinical evidence as the other three options. It remains a promising alternative for AGA and its use as an adjunct showcases that the treatment in trending in the right direction.  

As newer formulations continue to evolve, solutions that combine effective actives with optimized delivery systems, such as NOVOLUX™ Hair, represent the next step in AGA treatment by balancing efficacy, tolerability, and real-world usability.

Ultimately, successful long-term AGA management depends on selecting the appropriate molecule and delivery vehicle. Formulation, delivery, tolerability, and patient adherence are all important factors in patient adherence where neither outweighs the other. Effective treatment should be defined as the combination of biological targeting and practical execution.